| Literature DB >> 30925694 |
Gongsen Chen1, Xin Leng2, Juyuan Luo3, Longtai You4, Changhai Qu5, Xiaoxv Dong6, Hongliang Huang7,8, Xingbin Yin9, Jian Ni10,11.
Abstract
A MIL series metal‒organic framework (MOF), MIL-100(Fe), was successfully synthesized at the nanoscale and fully characterized by TEM, TGA, XRD, FTIR, DLS, and BET. A toxicological assessment was performed using two different cell lines: human normal liver cells (HL-7702) and hepatocellular carcinoma (HepG2). In vitro cytotoxicity of MIL-100(Fe) was evaluated by the MTT assay, LDH releasing rate assay, DAPI staining, and annexin V/PI double staining assay. The safe dose of MIL-100(Fe) was 80 μg/mL. It exhibited good biocompatibility, low cytotoxicity, and high cell survival rate (HL-7702 cells' viability >85.97%, HepG2 cells' viability >91.20%). Therefore, MIL-100(Fe) has a potential application as a drug carrier.Entities:
Keywords: HL-7702 cells; HepG2 cells; MIL-100(Fe); in vitro toxicity
Mesh:
Substances:
Year: 2019 PMID: 30925694 PMCID: PMC6480057 DOI: 10.3390/molecules24071211
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Schematic illustration of the construction of MIL-100(Fe).
The Effect of MIL-100 (Fe) on Various Cells, : biocompatible; : adverse effects.
| MOFs and MOFs-Objects | Cells | Dose (μg/mL) | Cell Viability | Toxic Grade | Reference |
|---|---|---|---|---|---|
| MIL-100(Fe) | PC3 | 100 (24 h) | 75% | low | Saad et al. [ |
| MIL/USPIO-cit(10) | PC3 | 100 (24 h) | 75% | low | Saad et al. [ |
| MIL-100(Fe) | HUVEC | 200 (24 h) | 100% | none | Stefan et al. [ |
| HMEC | 200 (72 h) | 85% | low | Stefan et al. [ | |
| MLE12 | 200 (24 h) | 10% | high | Stefan et al. [ | |
| MH-S | 200 (24 h) | 10% | high | Stefan et al. [ | |
| Gingival Fibroblasts | 200 (24 h) | 100% | none | Stefan et al. [ | |
| Human Schwann | 200(24 h) | 60% | medium | Stefan et al. [ | |
| MIL-100(Fe)@DOPC | HUVEC | 200 (24 h) | 100% | none | Stefan et al. [ |
| HMEC | 200 (72 h) | 60% | medium | Stefan et al. [ | |
| MLE12 | 200 (24 h) | 40% | high | Stefan et al. [ | |
| MH-S | 200 (24 h) | 20% | high | Stefan et al. [ | |
| nanoMIL-100(Fe) | MCF-7 | 100 (72 h) | 94% | none | Mahsa et al. [ |
| MIL-100(Fe) | CCRF-CEM | 5000(48 h) | >85% | low | Patricia et al. [ |
| RPMI-8226 | 5000(48 h) | >85% | low | Patricia et al. [ | |
| J744 | 5000(48 h) | >85% | low | Patricia et al. [ |
Figure 2Characteristics of MIL-100(Fe): (a) TEM, (b) TG, (c) XRD, (d) FTIR.
Figure 3(a) Size distribution of MIL-100(Fe); (b) BET isotherm of MIL-100(Fe) at 77 K.
Figure 4Effects of MIL-100(Fe) on HL-7702 cells’ viability and morphology: (a) MTT assay data, presented as mean ± SD of viability% of three independent experiments; (b) the effect of MIL-100(Fe) on LDH release of HL-7702 cells; (c) an evaluation of HL-7702 cells nuclear morphology by DAPI staining. (* p < 0.05 vs. Control.)
Figure 5Effects of MIL-100(Fe) on apoptosis in HL-7702 cells. (a) Flow cytometry detection of apoptosis with FITC-annexin V/PI double staining. (b) The percentages of viable, necrotic, and apoptotic HL-7702 cells after incubation with different concentrations of MIL-100(Fe) for 48 h. The data are expressed as means ± S.D. from three independent experiments. (* p < 0.05 vs. Control.)
Figure 6Effects of MIL-100(Fe) on HepG2 cells’ viability, membrane, and morphology: (a) In vitro cell viabilities of HepG2 cells after being incubated for 48 h with MIL-100(Fe); (b) LDH release of HepG2 cells incubated for 48 h with MIL-100(Fe); (c) nuclear morphology images of HepG2 cells after 48 h exposure to MIL-100(Fe). (* p < 0.05 vs. Control.)
Figure 7Effects of MIL-100(Fe) on apoptosis in HepG2 cells. (a) Flow cytometry detection of apoptosis with FITC-annexin V/PI double staining. (b) The percentages of viable, necrosis and apoptotic HepG2 cells after incubation with different concentrations of MIL-100(Fe) for 48 h. The data are expressed as means ± S.D. from three independent experiments. (* p < 0.05 vs. Control.)